Genmab — Oktober 2024
-
-
let me repeat from Jan early Sep/Morgan Stanley
on GEN3014 - And the good thing as quick as we can we will see that in the coming months because we are going to have the complete data set as agreed J&J to share with them. And we will flag that up to the market for sure. Next year we will see the detailed clinical data. Maybe we'll give you some top-line data this year.
right now -
AbbVie Trims Full-Year Earnings Guidance Due to R&D Milestone Costs https://www.biospace.com/business/abbvie-trims-full-year-earnings-guidance-due-to-r-d-milestone-costs part of that could go to Genmab, we'll see
-
@STockbull - Der er ingen kurs på Genmab om et år
-
Jeg lever af at sælge aktier, og hvis jeg har +30% på mine senest indkøbte Genmab-aktier, er det acceptabelt, da der jo er regninger, der skal betales. Jeg vil selvfølgelig forsøge at time salget til en høj RSI-værdi på dag- eller ugekortet. Det kan også være, at det helt korte mål bliver ændret undervejs.
-
beslutninger i svære situationer. Jeg har f.eks besluttet at beholde min Genmab position næste 12 mdr og så tage ny beslutning igen om 12 mdr eller hvis der sker noget uventet positivt eller negativt. At spekulere på hvorfor kursen falder og stiger er lidt spild af tid for ingen ved det helt precist.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind